gemcitabine + cisplatin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Biliary Tract Carcinoma

Conditions

Biliary Tract Carcinoma

Trial Timeline

Mar 1, 2003 → Sep 1, 2004

NCT ID

NCT00490399

About gemcitabine + cisplatin

gemcitabine + cisplatin is a phase 2 stage product being developed by Eli Lilly for Biliary Tract Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00490399. Target conditions include Biliary Tract Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00380588	Phase 2	Completed	Sep 1, 2006	Oct 1, 2008	Biliary Tract Cancer
NCT00191334	Phase 2	Completed	Dec 1, 2004	Dec 1, 2007	Ovarian Cancer
NCT00192101	Phase 2	Completed	Oct 1, 2004	Jul 1, 2005	Metastatic Breast Cancer
NCT00192036	Phase 2	Completed	Aug 1, 2004	Nov 1, 2009	Non Small Cell Lung Cancer
NCT00191620	Phase 2	Completed	Mar 1, 2004	May 1, 2006	Non-Small-Cell Lung Carcinoma
NCT00490880	Phase 2	Completed	Nov 1, 2003	Aug 1, 2004	Bladder Cancer
NCT00490659	Phase 2	Completed	Sep 1, 2003	Dec 1, 2004	Non-Small Cell Lung Cancer
NCT00490399	Phase 2	Completed	Mar 1, 2003	Sep 1, 2004	Biliary Tract Carcinoma
NCT00489996	Phase 2	Completed	Jan 1, 2003	Jun 1, 2005	Non-Small Cell Lung Cancer
NCT00191841	Phase 2	Completed	Dec 1, 2002	Feb 1, 2006	Carcinoma, Non-Small-Cell Lung
NCT00191763	Phase 2	Completed	Nov 1, 2002	Dec 1, 2005	Carcinoma, Non-Small-Cell-Lung Cancer
NCT00191815	Phase 2	Completed	Oct 1, 2002	Oct 1, 2007	Breast Cancer
NCT00123825	Phase 2	Completed	Jul 1, 2002	Oct 1, 2007	Gallbladder Cancer
NCT00191100	Phase 3	Completed	May 1, 2002	Apr 1, 2008	Cancer of Cervix
NCT00191126	Phase 3	Completed	Sep 1, 2000	Sep 1, 2007	Non-Small Cell Lung Cancer

Competing Products

20 competing products in Biliary Tract Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Camrelizumab and Apatinib Plus GP	Sun Pharmaceutical	Phase 1/2	41
Recaticimab and Adebrelimab + GP chemotherapy	Sun Pharmaceutical	Phase 2	52
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	52
E6011 + Placebo	Eisai	Phase 2	52
Lenvatinib	Eisai	Phase 2	52
gemcitabine + cisplatin	Eli Lilly	Phase 2	52
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IV	Eli Lilly	Phase 2	52
Baricitinib + Placebo	Eli Lilly	Phase 2	52
Abemaciclib	Eli Lilly	Phase 2	52
SHR-A1811	Jiangsu Hengrui Medicine	Phase 2	52
SHR1258	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
SHR-1210+GEMOX	Jiangsu Hengrui Medicine	Phase 2	52
Rilvegostomig + Durvalumab + Gemcitabine/Cisplatin	AstraZeneca	Phase 3	77
Durvalumab + Gemcitabine + Cisplatin	AstraZeneca	Pre-clinical	23
durvalumab	AstraZeneca	Phase 3	77
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabine	AstraZeneca	Phase 2/3	65
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + Tremelimumab	AstraZeneca	Phase 1	33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved